- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 6 - Emerging Treatments
Ms Young notes that while there is no cure, there has been tremendous progress in the development of newer drug classes.
Ms Young notes that while there is no cure, there has been tremendous progress in the development of newer drug classes. Patients have had response rates as high as 95% or greater with newer treatments. However, with disease progression and the relapse refractory setting, response rates can drop to 25% to 30%. There are also patients who don’t respond to specific agents, or respond then relapse very quickly.
“It’s really important to try and figure out what type of myeloma a patient may have, and the best way to treat, because there are some very low-risk types of myeloma that can be managed very well with standard therapies and then there are more aggressive types that really do need these newer agents and combinations,” says Ms Young.
Dr Goldberg discusses why a drug’s deliverability—among other factors—is important.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
